Evidence Library
Filter by drug, type, year, and open access.
Showing 101–150 of 427 results
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: systematic review and network meta-analysis — The Lancet (2022)• Drug: eszopicloneDOIPMID
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: systematic review and network meta-analysis — The Lancet (2022)• Drug: zolpidemDOIPMID
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: systematic review and network meta-analysis — The Lancet (2022)• Drug: ramelteonDOIPMID
- Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials — The Lancet Neurology (2022)• Drug: daridorexantDOIPMID
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: systematic review and network meta-analysis — The Lancet (2022)• Drug: zaleplonDOIPMID
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI) — Journal of Clinical Psychiatry (2022)• Drug: dextromethorphan-bupropionDOI
- Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy — Nature and Science of Sleep (2022)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
- Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: isocarboxazidDOI
- Real-world effectiveness of olanzapine/samidorphan: a systematic review — Schizophrenia Research (2022)• Drug: olanzapine-samidorphanDOI
- Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: selegilineDOI
- Consensus recommendations for MAOI safety and dietary management — Journal of Clinical Psychopharmacology (2022)• Drug: selegiline-transdermalDOI
- Practical strategies for MAOI therapy — Psychopharmacology Bulletin (2022)• Drug: tranylcyprominePMID
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine (2022)• Drug: tirzepatide-mounjaroDOI
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine (2022)• Drug: tirzepatide-zepboundDOI
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. — CNS Drugs (2021)• Drug: paliperidoneOpen accessDOIPMIDPMCID
- 6‑month paliperidone palmitate (PP6M): review — Review (2021)• Drug: paliperidone
- Effect of potent CYP2D6 inhibition on deutetrabenazine pharmacokinetics — European Journal of Clinical Pharmacology (2021)• Drug: deutetrabenazineDOI
- Phase III active- and placebo-controlled trial of vilazodone for major depressive disorder — Cureus (2021)• Drug: vilazodoneOpen accessDOIPMID
- A long-term, open-label study of valbenazine for tardive dyskinesia — CNS Spectrums (2021)• Drug: valbenazineDOI
- Lumateperone monotherapy for bipolar depression: a randomized, placebo-controlled clinical trial — Journal of Clinical Psychiatry (2021)• Drug: lumateperoneDOIPMID
- Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update — Drugs (2021)• Drug: gabapentinDOI
- Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update — Drugs (2021)• Drug: pregabalinDOI
- The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: gabapentin-enacarbilDOI
- The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: pramipexoleDOI
- The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)• Drug: ropiniroleDOI
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)• Drug: calcium-magnesium-potassium-and-sodium-oxybatesDOI
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)• Drug: sodium-oxybate-extended-releaseDOI
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)• Drug: sodium-oxybate-extended-releaseDOI
- Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy — Sleep (2021)• Drug: sodium-oxybate-extended-releaseDOI
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review — Medicines (2021)• Drug: benztropineOpen accessDOI
- Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review — Frontiers in Psychiatry (2021)• Drug: benztropineOpen accessDOI
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review — Medicines (2021)• Drug: trihexyphenidylOpen accessDOI
- Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review — Frontiers in Psychiatry (2021)• Drug: trihexyphenidylOpen accessDOI
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review — Medicines (2021)• Drug: amantadineOpen accessDOI
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: buprenorphineOpen access
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: buprenorphine-naloxoneOpen access
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: methadoneOpen access
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naltrexoneOpen access
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naltrexone-extended-releaseOpen access
- TIP 63: Medications for Opioid Use Disorder — SAMHSA (2021)• Drug: naloxoneOpen access
- Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement — JAMA (2021)• Drug: nicotineDOIPMID
- Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement — JAMA (2021)• Drug: vareniclineDOIPMID
- The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)• Drug: olanzapine-fluoxetineDOI
- Metabolic outcomes with olanzapine/samidorphan — Schizophrenia Bulletin (2021)• Drug: olanzapine-samidorphanDOI
- Long-Term Weight and Metabolic Effects of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: pooled analyses from phase 3 studies — Biological Psychiatry (2021)• Drug: olanzapine-samidorphanDOI
- Safety considerations with tranylcypromine — Annals of Clinical Psychiatry (2021)• Drug: tranylcyprominePMID
- CANMAT/ISBD guidance on valproate for bipolar disorder — Bipolar Disorders (2021)• Drug: valproate-divalproexDOI
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial — JAMA Psychiatry (2021)• Drug: zuranolonePMID
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine (2021)• Drug: semaglutide-ozempicDOI